Plagiarists Daniel Offen and Brainstorm Cell Therapeutics
The following email was not responded by Professor at Tel Aviv University Daniel Offen:
---------- Forwarded message ----------
From: Alexander Cherkasky <alexcherkasky@
Date: 2018-04-10 17:47 GMT+02:00
Subject: Alexander Cherkasky
To: danioffen@gmail.com
Dear Mr. Offen,
my name is Alexander Cherkasky, I am inventor and biologist and I am writing you, because I have evidence of your plagiarism and I ask your substantiated statement about my following evidence:
BrainStorm Cell Therapeutics (NASDAQ:BCLI), you are scientific founder of, has written on the website, that this biotechnology company develops innovative cell therapies debilitating neurodegenerative diseases.
You as the Chief Scientific Advisor of BrainStorm Cell Therapeutics, member of the Scientific Committee of the Israeli Society for Neuroscience and Professor at Tel Aviv University School of Medicine (the Neuroscience Laboratory at Tel Aviv University) have written the similar statements on your website.
The fact is, that you develop my inventions of new cell therapies. Thus your patents granted by error of examiners within the United States Patent and Trademark Office (USPTO) can be reexamined and invalidated and your patent applications will not be patents. It means, that BrainStorm will not be able to protect the products from competitors and this will lead to loss of investments.
The invention (your claim as your own) of genetically modified cells expressing different neurotrophic factors is not new and not inventive because of my published German patent document DE19951694 (for example claims 3 (VEGF) and 5 (BDNF)) claiming priority and novelty worldwide.
Thus your US patent US9365828 was granted by error of examiner and can be reexamined and invalidated. Also your WO2018015945 as well as US9474787, US8900574, US20160375098, US20130344041 and US20120009673 are not new and not inventive because of my DE19951694 (from the year 1999) for genetically modified cells for cell therapies.
By concealing my authorship, my inventorship and my priority BrainStorm Cell Therapeutics manipulates value in order to entice out more money from investors by false presentation, i.e. by fraud. You entice out investors' money by fraud, especially because you plagiaristically use my intellectual property. This your conduct is fraud in science and business.
Thus you must recognize your plagiarism publicly.
You must mention my name, my inventorship and my priority. It will be fair. My according inventions are basic and my according published patent document claims priority and novelty worldwide.
On my person:
I was born 1981 in Zaporozhye, Ukraine, living since 1996 in Dusseldorf, Germany, have finished Goethe-Gymnasium and Heinrich-Heine-University in Dusseldorf, my inventions include causal therapeutic solutions for combating cancer, viruses (both in and outside of cells), autoimmune and immune complex diseases, inventions for rejuvenation and tissue regeneration, inventions of novel multi-parallel diagnostic and gene sequencing systems, new materials and high-quality synthetic diamonds, and I have German patents and published American, international and German patent applications claiming priority and novelty worldwide.
Known media including Stern (The Star) and Laborjournal (from November 2016, pages 54-58, this the link http://www.laborjournal.
My patent documents were referenced in more than 27 patents of companies, universities and research institutes in 10 countries, in The USA, Canada, Spain, France, UK, Japan, China, Switzerland, Belgium and Germany.
The following is the partial list of these references:
1) My published patent document WO2006/136892 was referenced in the patent documents EP2447277 and WO2012055985 (for anti-HIV vaccines) of the Spanish company Laboratorios del Dr. Esteve and the research organization Fundacio Privada Institut de Reserca de la SIDA-Caixa
2) My patent DE19937512 was mentioned in the US Patent US7163658 (for sequencing of nucleic acid sequences) of the American inventor Rouvain Bension
3) DE19937512 mentioned in the US Patent US8153438 of Halcyon Molecular
4) DE19953696 mentioned in the US Patent US7557182 of the Canadian firm Angiochem
5) DE19953696 mentioned in the US Patent US7902156 of Angiochem
6) DE19953696 mentioned in the US Patent US8710013 of Angiochem
7) DE19953696 mentioned in the US Patent US8828925 of Angiochem
8) DE19953696 mentioned in the US Patent US8828949 of Angiochem
9) DE19953696 mentioned in the US Patent US8853353 of Angiochem
10) DE19953696 mentioned in the US Patent US8921314 of Angiochem
11) DE19953696 mentioned in the US Patent US8969310 of Angiochem
12) DE19953696 mentioned in the US Patent US9161988 of Angiochem
13) DE19953696 mentioned in the US Patent US9173891 of Angiochem
14) DE19953696 mentioned in the US Patent US9365634 of Angiochem
15) DE19953696 mentioned in the US Patent US9221867 of Angiochem
16) DE19822406 mentioned in the US Patent US8034766 of the American company E I du Pont de Nemours and Company and University College London
17) DE19822406 mentioned in the US Patent US8431526 of E I du Pont de Nemours and Company
18) DE19925052 mentioned in the US Patent US7999073 of the Swiss company Lonza
19) DE19925052 mentioned in the US Patent US7320859 of the German firm Amaxa sold to Lonza
20) DE19925052 mentioned in the US Patent US9260471 of the American company Sirna
21) DE19925052 mentioned in the US Patent US9181551 of Sirna Therapeutics
22) DE19925052 mentioned in the US Patent US9657294 of Sirna Therapeutics
23) US20080242565 mentioned in the US Patent US8273694 von Americans Jeffrey Brown, Joseph Duimstra and Jason Wells
24) DE10160248 (especially for the Fc-AChR fusion proteins against the autoimmune disease Myasthenia gravis) was mentioned in the US Patent US9243071 of the Japanese company Nihon Pharmaceutical (Tokyo, JP)
25) DE10162870 mentioned in the US Patent US8679500 of the Institute National de la Sante et de la Recherche Medicale (INSERM) (Paris, FR), Universite de Bretagne Occidentale (Brest, FR) and Centre National de la Recherche Scientifique (CNRS) (Paris, FR)
26) DE10162867 mentioned in the US Patent US8772254 of Devgen N.V. in Belgium
27) DE102007027596 mentioned in the Chinese Patent CN102718882 of the University Nanjing Agricultural
The search can be made for example in the patent literature data bank of the United States Patent and Trademark Office http://patft.uspto.gov/
I ask you to respond very soon.
If you do not respond within 5 days from this email I will take legal measures against your fraud. These measures will include making publicity based on your fraud, i.e. on your plagiarism, your concealing of your plagiarism and the according manipulation of value.
Sincerely,
Alexander Cherkasky
Dipl.-Biol. (M.Sc.) Alexander Cherkasky
Prinz-Georg-Str. 5
40477 Duesseldorf
Tel: +49 211 482179
Email: alexcherkasky@
Kommentare
Kommentar veröffentlichen